Posts

Paragraph IV Updates 2026: Camzyos Patent Challenges & REBYOTA IP Ruling

Image
Two minutes of quick reading Pharma IP & Regulatory Roundup 2026: Blockbuster Patent Challenges and Landmark REBYOTA Decision The global pharmaceutical landscape in June 2026 continues to present complex legal strategies and high-stakes patent battles . From critical Paragraph IV challenges against blockbuster drugs to a definitive U.S. District Court verdict on damages for faecal microbiota transplantation (FMT) therapy, generic and innovator companies alike face shifting operational dynamics . Below is an analytical summary of the most impactful regulatory and intellectual property (IP) developments . 1. Day-One Paragraph IV Filings Target BMS' Blockbuster Camzyos In a major development for the generic drug industry, the USFDA's Paragraph IV database was updated on June 9, 2026, revealing that seven generic applicants simultaneously submitted Abbreviated New Drug Applications (ANDAs) with Paragraph IV certifications targeting mavacamten capsules ( 2.5 mg , 5 mg , 10...
Read more

Pharma Regulatory & IP Update 2026: FDA CGT Approvals, GLP-1 Wars, and EPO Case Law

Image
Two minutes of quick reading Pharma Regulatory & IP Digest: 2026 CGT Trends, GLP-1 Breakthroughs, and EPO Patent Rulings This comprehensive digest analyses the critical updates impacting generic manufacturers, drug compounders, and IP strategists today. 1. The Competitive Generic Therapy (CGT) Market Race The traditional generic drug market is frequently characterised as a "race to the bottom," with heavy multi-competitor volume often triggering severe price erosions of 80% to 95% . To promote generic development in areas with historically inadequate competition, the FDA utilises the Competitive Generic Therapy (CGT) pathway under the FDA Reauthorisation Act (FDARA) . Securing a CGT designation offers a highly lucrative incentive: 180 days of market exclusivity . However, recent data highlights a stark commercial reality: securing a designation does not guarantee market exclusivity, and capturing the prize requires flawless operational timing . Exclusivity Granted vs...
Location: Mumbai, Maharashtra, India
Read more